Drug Patents owned by Johnson Johnson Visn

1. Drug name - ACUVUE THERAVISION WITH KETOTIFEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9474746 JOHNSON JOHNSON VISN Methods for stabilizing oxidatively unstable compositions
Mar, 2028

(5 years from now)

US9962376 JOHNSON JOHNSON VISN Methods and ophthalmic devices used in the treatment of ocular allergies
Jun, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Feb 25, 2025

Drugs and Companies using KETOTIFEN FUMARATE ingredient

Market Authorisation Date: 25 February, 2022

Treatment: NA

Dosage: DRUG-ELUTING CONTACT LENS ;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 19MCG BASE DRUG-ELUTING CONTACT LENS ;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in